Initiation of buprenorphine during incarceration and retention in treatment upon release
详细信息 查看全文
- 作者：Nickolas Zaller ; Ph.D.<sup>asup><sup> ; sup><sup>bsup><sup> ; sup><sup>nzaller@lifespan.orgsup> ; Michelle McKenzie ; M.P.H.<sup>asup><sup> ; sup><sup>bsup> ; Peter D. Friedmann ; M.D. ; M.P.H.<sup>bsup><sup> ; sup><sup>csup> ; Traci C. Green ; Ph.D.<sup>bsup><sup> ; sup><sup>csup> ; Samuel McGowan ; B.A.<sup>asup> ; Josiah D. Rich ; M.D. ; M.P.H.<sup>asup><sup> ; sup><sup>bsup>
- 关键词：Buprenorphine/naloxone ; Incarceration ; Opiates ; Addiction ; HIV
- 刊名：Journal of Substance Abuse Treatment
- 出版年：2013
- 出版时间：August, 2013
- 年：2013
- 卷：45
- 期：2
- 页码：222-226
- 全文大小：234 K
文摘
We report here on a feasibility study of initiating buprenorphine/naloxone prior to release from incarceration and linking participants to community treatment providers upon release. The study consisted of a small number of Rhode Island (RI) prisoners (N = 44) diagnosed with opioid dependence. The study design is a single arm, open-label pilot study with a 6-month follow up interview conducted in the community. However, a natural experiment arose during the study comparing pre-release initiation of buprenorphone/naloxone to initiation post-release. Time to post-release prescriber appointment (mean days) for initiation of treatment outside Rhode Island Department of Corrections (RIDOC) versus inside RIDOC was 8.8 and 3.9, respectively (p = .1). Median post release treatment duration (weeks) for outside RIDOC versus inside RIDOC was 9 and 24, respectively (p = .007). We conclude that initiating buprenorphine/naloxone prior to release from incarceration may increase engagement and retention in community-based treatment.